S
5.06
-0.20 (-3.71%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Sagimet Biosciences Inc. - Seri | 看跌 | 看跌 |
AIStockmoo 评分
0.3
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.25 |
|
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.03% |
| 机构持股比例 | 44.74% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Woodline Partners Lp | 30 Sep 2025 | 1,501,357 |
| Blue Owl Capital Holdings Lp | 31 Dec 2025 | 1,243,877 |
| Baker Bros. Advisors Lp | 30 Sep 2025 | 952,996 |
| Hhlr Advisors, Ltd. | 30 Sep 2025 | 724,800 |
| Siren, L.L.C. | 30 Sep 2025 | 724,771 |
| Schonfeld Strategic Advisors Llc | 30 Sep 2025 | 523,774 |
| Affinity Asset Advisors, Llc | 30 Sep 2025 | 350,000 |
| Readystate Asset Management Lp | 30 Sep 2025 | 325,359 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 35.00 (Citizens, 592.38%) | 购买 |
| 中 | 28.00 (453.91%) | |
| 低 | 8.00 (Barclays, 58.26%) | 保留 |
| 平均值 | 24.75 (389.61%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 6.68 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 03 Feb 2026 | 27.00 (434.12%) | 购买 | 6.56 |
| HC Wainwright & Co. | 03 Feb 2026 | 29.00 (473.69%) | 购买 | 6.56 |
| Barclays | 28 Jan 2026 | 8.00 (58.26%) | 保留 | 5.86 |
| Citizens | 14 Nov 2025 | 35.00 (592.38%) | 购买 | 7.75 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合